Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 21, 2016 06:59 ET | Source: Calithera Biosciences, Inc.

Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology...
December 12, 2016 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces Key Management Changes

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
December 09, 2016 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Host Conference Call and Webcast to Review Data Presented at the San Antonio Breast Cancer Symposium and EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
December 06, 2016 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports CB-839 Phase I Triple Negative Breast Cancer Combination Data at the 2016 San Antonio Breast Cancer Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
December 02, 2016 07:01 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces CB-839 Preclinical Data Selected for Presentation at the 58th American Society of Hematology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the discovering and developing novel...
November 29, 2016 18:01 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports CB-839 Phase I Renal Cell Carcinoma Combination Data at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
November 11, 2016 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces Four Abstracts Selected for Presentation at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
November 09, 2016 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Third Quarter 2016 Financial Results and Recent Highlights, and Raises Year-end Cash Guidance

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
November 02, 2016 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
September 22, 2016 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Roundtable

SOUTH SAN FRANCISCO, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...